药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

交易中 05-19 15:13:06

47.780

-2.020

-4.06%

最高53.800	最低45.240	成交量310.84万
今开47.380	昨收49.800	日振幅17.19%
总市值193.03亿	流通市值147.64亿	总股本4.04亿
成交额1.51亿	换手率1.01%	流通股本3.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":47.78,"timestamp":1779174668141,"preClose":49.8,"halted":0,"volume":3108400,"delay":0,"changeRate":-0.04056224899598386,"floatShares":309000000,"shares":404000000,"eps":-0.8745070951978198,"marketStatus":"交易中","change":-2.02,"latestTime":"05-19 15:13:06","open":47.38,"high":53.8,"low":45.24,"amount":150914955,"amplitude":0.171888,"askPrice":47.8,"askSize":1000,"bidPrice":47.52,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.8745070951978198,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779178200000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":49.8,"openAndCloseTimeList":[[1779154200000,1779163200000],[1779166800000,1779177600000]],"volumeRatio":2.316932,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617/tweets","defaultTab":"tweets","newsList":[{"id":"2636891168","title":"港股异动 | 药捷安康-B (02617) 现跌超3% 拟折让约18%配股净筹1.52亿港元 年内第三次配股集资","url":"https://stock-news.laohu8.com/highlight/detail?id=2636891168","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636891168?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:17","pubTimestamp":1779160655,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药捷安康-B 今早股价剧烈波动，盘中低见45.24港元一度跌逾9%，随后强势反弹至53.8港元，现股价再度走低。截至发稿，跌3.14%，报48.24港元，成交额1.29亿港元。消息面上，药捷安康今早公布，拟向不少于六名承配人配售383.6万股新股，占扩大后约0.94%，每股配售价40.83港元，较5月18日收市价49.8港元折让约18.01%。假设配售股份获悉数配售，所得款项总额约1.57亿港元，净额约1.52亿港元。值得注意的是，药捷安康此次配股是2026年内第三次进行配股集资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","02617","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636889414","title":"港股速报 | 恒指小幅高开 百度迎利好 阿里早盘涨超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636889414","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636889414?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:12","pubTimestamp":1779160358,"startTime":"0","endTime":"0","summary":"5月19日，港股市场表现平稳，恒指早盘小幅高开。恒生指数开盘报25693.37点，上涨18.19点，涨幅0.07%；恒生科技指数开盘报4838.36点，下跌6.58点，跌幅0.14%。焦点公司方面，百度集团-SW（HK09888）迎来利好，早盘涨超2%。消息面，百度集团发布2026年第一季度财报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741723547.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741723547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4524","LU1880383366.USD","LU1515016050.SGD","09115","BABA","BK4581","BK4588","IE00BF5LJ272.USD","LU0348814723.USD","LU1282648689.USD","07200","LU1048596156.SGD","BK4579","LU0640798160.USD","LU0456842615.SGD","BK4220","LU1008478684.HKD","KBDU","LU0072913022.USD","LU0106959298.USD","LU2148611432.USD","LU0501845795.SGD","HSTECH","BK4504","KBAB","82800","BK4602","BK4575","HHImain","ALBmain","LU0128525689.USD","09888","LU0287142896.SGD","LU0348816934.USD","LU0821914370.USD","BK4558","LU1769817179.HKD","LU0738911758.USD","LU0067412154.USD","03037","LU0545039389.USD","LU2226246903.HKD","LU0553294199.USD","IE00BFMHRM44.USD","LU1023057109.AUD","LU1105468828.SGD","LU1152091754.HKD","LU0052756011.USD","BK4505","LU0359202008.SGD","LU0918141887.USD","BIDG","LU1003077747.HKD","BABW","BK4533","LU0251143458.SGD","LU0310800965.SGD","LU1115378108.SGD","MCHmain","LU1242518931.SGD","LU1688375341.USD","BK4527","LU0797268264.HKD","LU0661504455.SGD","07300","BABX","BK4574","HSI","LU0047713382.USD","LU0880133367.SGD","LU1267930227.SGD","LU1823568750.SGD","BK4534","BK4548","03115","LU1152091168.USD","BIDU","MHImain","LU0173614495.USD","BK4526","BK4587","BK4538","02800","BK4607","LU0072462343.USD","LU0328353924.USD","07500","BK4502","BK4122","LU1769817096.USD","BK4514","BABO","03419","IE00B0JY6N72.USD","LU1048588211.SGD","09988","BK4535","LU0918141705.HKD","LU1235294995.USD","BK4543","BK4585","LU0949170772.SGD","02617","02833","LU0979878070.USD","LU1051768304.USD","LU1051769294.HKD","LU0651947912.USD","BK4552","BK4565","LU1046422090.SGD","BK4554","LU0651946864.USD","BK4614","LU1242518857.USD","BK4531","BBYY","LU0359201612.USD","BK4503","513600","BABU","BK4077","LU1046421795.USD","BK4612","83115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151064397","title":"异动解读 | 药捷安康-B盘中大涨6.12%，市场看好其配售筹资用于核心产品开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1151064397","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151064397?lang=zh_cn&edition=full","pubTime":"2026-05-19 10:49","pubTimestamp":1779158954,"startTime":"0","endTime":"0","summary":"药捷安康-B（02617）今日盘中股价大幅上涨6.12%，引起了投资者的关注。消息面上，公司于交易时段前发布公告，宣布与配售代理订立配售协议，计划以每股40.83港元的价格配售约383.6万股H股，预计所得款项净额约为1.52亿港元。公司表示，此次配售所得款项净额的约90%将用于其核心产品Tinengotinib新适应症的开发，其余约10%用于营运资金及一般企业用途。市场分析认为，尽管配售价格较前一日收盘价有所折让，但资金将主要用于核心在研药物的临床开发，这增强了投资者对公司未来研发管线推进及长期增长潜力的信心，从而推动了股价的积极表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187670148","title":"异动解读 | 药捷安康-B盘中大跌5.22%，因折让约18%配股筹资","url":"https://stock-news.laohu8.com/highlight/detail?id=1187670148","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187670148?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:36","pubTimestamp":1779154600,"startTime":"0","endTime":"0","summary":"药捷安康-B今日盘中大跌5.22%，引起了市场的广泛关注。消息面上，公司于交易时段前宣布，拟以每股40.83港元的价格配售383.6万股新H股，配售价较前一交易日收盘价折让约18.01%，预计净筹资约1.52亿港元。折价配售新股通常会对二级市场股价造成短期压力，因稀释效应及较低的配售价可能影响投资者信心。根据公告，此次配售所得款项净额约90%将用于公司核心产品Tinengotinib新适应症的开发，其余10%用于营运资金及一般企业用途。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636002819","title":"药捷安康-B(02617)拟折让约18.01%配售383.6万股 净筹1.52亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636002819","media":"智通财经","labels":["shareholding"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636002819?lang=zh_cn&edition=full","pubTime":"2026-05-19 06:37","pubTimestamp":1779143838,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，于2026年5月19日，本公司与配售代理订立配售协议，据此，配售代理有条件同意作为本公司的配售代理，按尽力基准促使承配人按每股配售股份40.83港元的配售价购买383.6万股配售股份。预期配售代理将促使不少于六名承配人认购配售股份。配售股份的承配人须由配售代理根据上市规则的要求厘定。假设所有配售股份获悉数配售及待完成后，预期配售事项所得款项总额及所得款项净额将分别约为 1.57亿港元及1.52亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B(02617)拟折让约18.01%配售383.6万股 净筹1.52亿港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183160539","title":"药捷安康-B预计全球发售所得款项总额约1.566亿港元，净额约1.521亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183160539","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183160539?lang=zh_cn&edition=full","pubTime":"2026-05-19 06:32","pubTimestamp":1779143536,"startTime":"0","endTime":"0","summary":"药捷安康-B（股票代码：02617）全球发售的预计所得款项总额及净额已公布。根据相关数据，本次发售的所得款项总额预计约为1.5662亿港元。扣除各项包销费用、佣金及其他相关开支后，公司预计将获得的净所得款项约为1.5213亿港元。\n此次资金募集旨在支持公司的研发活动、业务拓展及一般营运资本需求。所得款项的运用将遵循公司既定的发展战略，以推动其核心管线产品的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636947580","title":"药捷安康-B(02617)在自然杂志子刊发表核心产品替恩戈替尼单药及联合阿替利珠单抗治疗晚期实体瘤的探索性临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2636947580","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636947580?lang=zh_cn&edition=full","pubTime":"2026-05-17 18:44","pubTimestamp":1779014647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，在Nature Communications发表核心产品替恩戈替尼单药及联合阿替利珠单抗治疗晚期实体瘤的探索性临床结果。替恩戈替尼单药治疗A组的客观缓解率达到为16.7%，联合阿替利珠单抗用药B组的客观缓解率为22.6%，均展现出抗肿瘤活性。对于既往经FGFR抑制剂治疗后进展、携带FGFR2融合突变的胆管癌患者，替恩戈替尼单药治疗客观缓解率达66.7%。上述研究结果支持进一步推进替恩戈替尼单药及联合免疫疗法的临床开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160900405","title":"药捷安康-B更新4月股份变动月报表，总股本增至404,082,633股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160900405","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160900405?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:26","pubTimestamp":1778066760,"startTime":"0","endTime":"0","summary":"药捷安康 (南京)科技股份有限公司（股票代码：02617）于2026年5月6日披露了截至2026年4月30日的证券变动月报表。报告显示，公司H股本月由303,766,673股增至308,851,673股，较上月增加5,085,000股；非上市股份维持在95,230,960股不变。公司法定/注册股本因此增至404,082,633股。\n本月内，公司无股份购回、注销或库藏股变动，也无新的股份期权或其他股权激励计划的相关变动信息。公司于公告中确认，其已遵守香港联合交易所有限公司《上市规则》及其他适用的法律法规。公告由公司联席公司秘书黄荻签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153005887","title":"药捷安康-B公布4月股份变动月报，H股增至308,851,673股","url":"https://stock-news.laohu8.com/highlight/detail?id=1153005887","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153005887?lang=zh_cn&edition=full","pubTime":"2026-05-06 15:53","pubTimestamp":1778053987,"startTime":"0","endTime":"0","summary":"2026年5月6日，药捷安康(南京)科技股份有限公司发布截至2026年4月30日止月份之证券变动月报表。公告显示，报告期内公司注册股本由人民币398,997,633元相应增至人民币404,082,633元，其中H股由303,766,673股增至308,851,673股，增发5,085,000股，非上市股份则维持在95,230,960股不变。截至4月底，公司法定/注册股本总额为人民币404,082,633元，H股及非上市股份公开流通量满足香港联合交易所有限公司相关上市规则要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631687321","title":"药捷安康上市不到一年三度融资：折价18%配股再募2.9亿港元，前次资金未用再伸手","url":"https://stock-news.laohu8.com/highlight/detail?id=2631687321","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631687321?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:04","pubTimestamp":1777543440,"startTime":"0","endTime":"0","summary":"2026年4月14日盘后，港股18A未盈利生物科技公司药捷安康-B再度宣布新一轮配售方案，拟以每股57.03港元向不少于六名专业及机构投资者配售508.5万股新H股，募资总额约2.90亿港元，净额约2.82亿港元。这是公司自2025年6月登陆港交所以来，不到一年时间内启动的第二次再融资，加上IPO募集资金，已累计融资6.3亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-04-30/doc-inhwhrai4125376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110590242","title":"药捷安康-B：4月21日发行约508.5万股H股，总额约2.90亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110590242","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110590242?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:12","pubTimestamp":1776769948,"startTime":"0","endTime":"0","summary":"2026年4月21日，药捷安康(南京)科技股份有限公司（02617）公告披露已通过配售方式发行5,085,000股H股，占发行前已发行股本约1.67%，每股发行价为57.03港元，合计募资约2.90亿港元。发行完成后，公司已发行股本增至308,851,673股。\n据公告，本次发行基于公司于2025年8月4日举行股东周年大会所授出的一般授权进行。公司同时确认，已遵守香港联交所证券上市规则及相关法律法规。公告由公司董事长兼首席执行官吴永谦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B：4月21日发行约508.5万股H股，总额约2.90亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033558","title":"药捷安康-B(02617)完成配售合共508.5万股配售股份 净筹约2.82亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033558","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629033558?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:05","pubTimestamp":1776769532,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，配售协议所载所有条件均已达成，有关配售事项已于2026年4月21日完成。配售代理已成功以每股配售股份57.03港元的配售价向不少于六名承配人配售合共508.5万股配售股份。508.5万股配售股份相当于紧接完成前现有已发行H股数目的约1.67%及现有已发行股份数目的1.27%，及经配发及发行配售股份扩大后的已发行H股数目的约1.65%及已发行股份数目的约1.26%。配售事项所得款项总额及所得款项净额分别约为2.9亿港元及2.82亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629777358","title":"药捷安康-B(02617)在2026年AACR展示谱系重塑作为HR+乳腺癌内分泌治疗的耐药机制以及替恩戈替尼的临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629777358","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629777358?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:04","pubTimestamp":1776729879,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 公布，公司在2026年美国癌症研究协会年会上以壁报形式披露了谱系可塑性作为HR+乳腺癌内分泌耐药的驱动机制及其临床转化意义。上述发现支持双靶点FGFR-JAK阻断作为克服谱系可塑性驱动的内分泌耐药的有效策略。目前，替恩戈替尼联合内分泌治疗晚期HR+乳腺癌的II期临床试验正在进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617","BK4203","HR","BK4225"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628781605","title":"格隆汇沽空预警榜 | 4月16日","url":"https://stock-news.laohu8.com/highlight/detail?id=2628781605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628781605?lang=zh_cn&edition=full","pubTime":"2026-04-18 02:15","pubTimestamp":1776449700,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日大市沽空比例为20.22%，过去两个月大市日均沽空比例为20.98%。其中，价值黄金-R、GX创新蓝筹十强、华夏沪深三百-U沽空比率排名前三位，分别为100.00%、100.00%、100.00%。盈富基金、南方恒生科技、恒生中国企业的沽空金额排名前三位，分别为55.27亿、37.99亿、35.30亿。维升药业-B、应星控股、碧桂园的偏离值排名前三位，分别为7.83、4.67、4.28。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/04/18021556797242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MPNGY","02800","MCHmain","BYDDY","ALBmain","518880","80020","HYDD.SI","81211","GCmain","NUGT","METmain","MIUmain","HBBD.SI","HMTD.SI","02828","00700","002594","09188","09888","03750","81810","82318","03690","89888","00373","01810","03133","TCHmain","HXXD.SI","SGUmain","BIDU","03422","02617","03033","09988","SGCmain","89988","03185","01440","03453","159934","01330","XIACY","HTCD.SI","01426","BABA","02007","01211","GLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227042","title":"药捷安康-B(02617)：替恩戈替尼单药治疗晚期胆管癌患者确证性III期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227042","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227042?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:41","pubTimestamp":1776422489,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)单药治疗晚期胆管癌患者的确证性III期临床研究，于近日完成首例患者给药。本试验为在中国开展的一项评价替恩戈替尼对比化疗用于既往经一线系统性治疗后复发或进展的、携带FGFR2融合╱重排或突变的、手术不可切除的晚期或转移性肝内胆管癌患者的疗效与安全性的随机对照、开放、多中心III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","BK4134","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627209684","title":"药捷安康-B(02617)拟折让约18.00%发行508.5万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2627209684","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627209684?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:02","pubTimestamp":1776207769,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，于2026年4月14日，本公司与配售代理订立配售协议，配售代理有条件同意作为本公司的配售代理，按尽力基准促使承配人按每股配售股份57.03港元的配售价购买508.5万股配售股份。每股配售股份57.03港元的配售价较股份于2026年4月14日在联交所所报的收市价每股H股69.55港元折让约18.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953833","title":"药捷安康-B(02617)建议采纳H股股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953833","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625953833?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:19","pubTimestamp":1775564350,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，董事会已于2026年4月7日举行的董事会会议上议决建议采纳H股股份奖励计划。奖励的授予将透过库存股或本公司发行的新H股(统称“新股”)或现有H股满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177369602","title":"药捷安康-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1177369602","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177369602?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:46","pubTimestamp":1775116002,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年4月2日披露的月报表显示，截至2026年3月31日，公司法定注册股本总额为398,997,633股，与上月底持平。其中，包括303,766,673股H股和95,230,960股非上市股份，两者均无变动。\n报告期内未有新增发行、购回或注销股份，亦不存在任何库存股变动；公司无期权、权证或可换股票据相关业务变动。公司确认其所有交易均遵守香港联合交易所《上市规则》及相关法律规定。\n本次公告由联席公司秘书黄荻签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623586909","title":"药捷安康-B(02617)建议委任冯维波为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2623586909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623586909?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:54","pubTimestamp":1774958093,"startTime":"0","endTime":"0","summary":"因个人工作安排，郑哲兰女士已决定辞任独立非执行董事、董事会薪酬与考核委员会主席以及董事会审计委员会及提名委员会成员。经提名委员会的资格审查后，于2026年3月31日召开的董事会会议上，公司审议及批准建议委任冯维波先生为独立非执行董事并同意提名冯维波先生为独立非执行董事候选人，同时兼任薪酬与考核委员会主席以及审计委员会及提名委员会成员，其任期自公司于应届股东周年大会上批准之日起至3年后止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623226588","title":"药捷安康-B(02617)发布2025年度业绩，净亏损2.96亿元，同比扩大7.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623226588","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623226588?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:46","pubTimestamp":1774953986,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布截至2025年12月31日止年度业绩，其他收入及收益同比下降48.6%至2025年度的920万元，该等减少主要是由于银行存款利息及理财收入减少500万元，政府补助较同期减少370万元。净亏损2.96亿元，同比扩大7.8%;每股基本亏损0.76元。研发成本同比上升1%至2025年度的2.468亿元，保持相对稳定，略有增长，主要是公司聚焦核心产品与关键技术研发，优化资源配置，持续提升产品竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.1059},{"period":"1month","weight":-0.2803},{"period":"3month","weight":-0.2655},{"period":"6month","weight":-0.7544},{"period":"1year","weight":2.7871},{"period":"ytd","weight":-0.5666}],"compareEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0185},{"period":"3month","weight":-0.0386},{"period":"6month","weight":-0.006},{"period":"1year","weight":0.0998},{"period":"ytd","weight":0.0017}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}